ATNM News and Press, Actinium Pharmaceuticals Inc. From 11/04/21

Actinium Pharmaceuticals (NYSE:ATNM) announces that the Phase 1 trial studying Actimab-A with the salvage chemotherapy CLAG-M in patients with relapsed or refractory acute myeloid leukemia ((r/r AML)) who are fit for intensive therapy has completed the planned dose escalation and patient enro...

Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy - Updated Phase 1 data to be presented at ASH with clinical development update expected before year end ...

Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting - Data from the fully enrolled Pivotal Phase 3 SIERRA trial for Iomab-B, Phase 1 Actimab-A and CLAG-M trial and Pha...

Actinium Announces Two Abstracts Highlighting Combinations of CD47 Targeting Immunotherapy with Targeted Radiotherapies in Solid Tumors and Blood Cancers Accepted for Presentation at Society for Immunotherapy for Cancer (SITC) Conference PR Newswire NEW YORK , Oct.&#...

Actinium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29th PR Newswire NEW YORK , Sept. 28, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the devel...

Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs Focused on Solid Tumors and Novel Combinations with Checkpoint Inhibitors and Radioconjugates Actinium Announces Expansion of R&D Team and Facilities to Accelerate Research Programs F...

Actinium to Present at Four Upcoming Investor Conferences - Company to highlight recently completed Phase 3 SIERRA trial and upcoming milestones PR Newswire NEW YORK , Sept. 20, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("A...

GreenSky (NASDAQ:GSKY) +48% Goldman Sachs to acquire GreenSky Birks Group (NYSE:BGI) +13%. Innate Pharma IPHA +12% on 1H earnings. LM Funding America (NASDAQ:LMFA) +12% expands into cryptocurrency mining business MeaTech 3D (NASDAQ:MITC) +11% manufactures over half a ...

Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B - Data updates expected in 4Q:2021 with topline data in mid-2022 - 100% of patients receiving Iomab-B accessed bone marrow transplant and engrafted without delay compared to 18% of patients receivin...

Actinium Pharmaceuticals Inc. (Delaware) (NYSE American:ATNM) traded today at a new 52-week low of $6.62. So far today approximately 128,000 shares have been exchanged, as compared to an average 30-day volume of 196,000 shares. Actinium Pharmaceuticals Inc is a biopharmaceutical company ...